Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast, including the exclusive right to commercialize any resulting products.
Download our corporate fact sheet intended for investors and shareholders.
DownloadThe information on the website you are about to enter may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries. You are solely responsible for your interactions with that website.
Before you download the Arcutis corporate fact sheet, please note that marketing authorizations and availability of products may differ between Canada and other countries.
Please note that the information in the environment, social, and governance (ESG) report you are about to download is US based. Marketing authorizations and availability of products may differ between Canada and other countries.
